PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-26

Study Completion Date

2021-09-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A total of 440 patients meeting enrollment criteria with a primary episode of C. Difficile Infection (CDI) will be enrolled across 3 sites. The total study time period for study procedures followed by clinical monitoring is anticipated to be about 24 months (biomarker assays and other analyses may be completed after the 24 month time period). All participants will receive oral antibiotics for CDI under the care of their physician. After consenting to participate in the study, participants will be randomized to receive either misoprostol (200 mcg po BID) or matching placebo for 14 days. Participants will be monitored for a total time-period of approximately 9 weeks with the goal of monitoring for recurrence of CDI during an 8-week follow-up period from the time that the course of antibiotic treatment is completed. Patients will have blood and stool samples (or rectal swabs if participants are unable to provide a stool sample) collected throughout the study to assess adherence, biomarkers, and to confirm recurrence of CDI (if necessary).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

NCT03005379

Clostridium Difficile Infection

TERMINATED PHASE2/PHASE3

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

NCT03110133

Clostridium Difficile Infection Recurrence

COMPLETED PHASE2

Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum

NCT02343328

Clostridium Difficile

TERMINATED PHASE1

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

NCT02117570

Clostridium Difficile Associated Disease

COMPLETED PHASE2

Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy

NCT02472600

Intestinal Colonization With Multidrug-resistant Bacteria

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clostridium Difficile

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Drug (Misoprostol)

Group Type EXPERIMENTAL

Misoprostol 100Mcg Tab

Intervention Type DRUG

Two 100mcg capsules twice per day

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Two capsules twice per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Misoprostol 100Mcg Tab

Two 100mcg capsules twice per day

Intervention Type DRUG

Placebo

Two capsules twice per day

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Episode of CDI, defined as ALL of the following:

1. ≥3 unformed (loose or watery) stools with a 24-hour period;
2. A documented positive C. difficile toxin assay (enzyme immunoassay \[EIA\] or cell cytotoxicity assay) or NAAT for toxigenic C. difficile from a stool sample collected while the subject was symptomatic; and
3. No other explanation for diarrhea (e.g. laxatives).
2. At the time of enrollment, on a course of oral antibiotics commonly used for treatment of CDI.
3. Be ≥18 years of age.
4. Be able to provide signed and dated informed consent.
5. Must be able to read and understand English.

Exclusion Criteria

1. Have not recovered from primary episode of CDI at time of enrollment, defined as presence of EITHER of the following:

1. ≥3 unformed (loose or watery) stools during the 24 hours prior to randomization, OR
2. Abdominal discomfort (more than mild) present during the 24 hours prior to randomization.
2. Have received, or plans to use, any of the following for treatment of the primary episode of CDI:

1. Any immunotherapy (e.g., intravenous immunoglobulin, bezlotoxumab).
2. Any toxin-binding therapy (e.g., cholestyramine \[Questran\], colestipol \[Colestid\], or colesevelam \[Welchol\]).
3. Current or planned treatment with prostanoid therapy.
4. Diarrhea caused by another infection or diarrhea caused by an underlying gastrointestinal disorder.
5. Have any contraindication to oral/enteral therapy (e.g., severe nausa/vomiting or ileus).
6. Have an absolute neutrophil count \<500/mm3 \[1.0 x 109/L\] within 30 days of screening.
7. Require or have an anticipated need for mechanical ventilation or vasopressors for hemodynamic support during the study.
8. Pregnant, nursing, or planning to become pregnant.
9. Inability to understand the requirements of the study, inability to abide by the study restrictions.
10. Have any clinically significant medical or surgical condition that in the investigator's opinion could interfere with the administration of study drug, interpretation of study results, or compromise the safety or well-being of the subject.
11. Known hypersensitivity to misoprostol.
12. Be unwilling or unable to follow study procedures (e.g., study visits, swallow the study drug/placebo, provide stool samples and undergo phlebotomy according to the study schedule, and reliably report information by phone), or not have a caregiver who can ensure that study procedures are followed.
13. If female, be pre-menopausal (cessation of menses less than or equal to 1 year) and not surgically/medically sterile or not following acceptable non-hormonal method of birth control such as abstinence, intrauterine device, or barrier control for at least 1 complete menstrual cycle before the screening visit, or not using estrogen/progestin containing products for at least 2 months before the screening visit through discharge from the study.
14. Unreliable access to telephone service to allow for contact with study personnel.
15. Inability to be seen for routine clinical care either as an outpatient or inpatient.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No